3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
Advertisement
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
AUPH Aurinia Pharmaceuticals Inc
43,656
$5.30
$0.09
(1.67%)
| Watchers | 43,656 |
| 52-Wk Low | $4.71 |
| 52-Wk High | $12.43 |
| Market Cap | $758M |
| Volume | 761,208.00 |
| 52-Wk High | $12.43 |
| 52-Wk Low | $4.71 |
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024Business Wire • 3 days ago
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in...
Share to Feed
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued the following letter to shareholders in response to a letter from Lucien Selce. Dear Fellow Shareholders: Aurinias...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Jefferies Global Healthcare Conference in New York from June 4-6, 2024. Aurinia...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2024. Amounts are expressed in U.S. dollars. Total net...
In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the FDA has approved a label update for LUPKYNIS. The updated label no longer includes language indicating...
NOTE: The new presentation time for Aurinias presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conferences is 4:00 to 4:30 PM Eastern Time. This event is presentation only. Webcast...